anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Coronary artery disease continues to be the most common cause of morbidity and mortality in the occidental world. Treatment of coronary atherosclerotic disease has been significantly advanced by interventional cardiology, and in particular the advent of coronary arterial stents. In comparison to angioplasty alone, stents have reduced the incidence of angiographic as well as clinical restenosis, the recurrence of angina, the need for coronary arterial bypass graft (CABG) surgery, the need for repeat revascularization and the occurrence of major adverse cardiac events (MACE).However,problems remain due to failure to achieve optimal stent apposition and normal myocardial reperfusion. Early stent malapposition may be due to incomplete expansion or undersizing of balloon-expandable stents. Several studies have emphasized the importance of early malapposition in the setting of ST elevation MI, in which substantial thrombotic burden and the presence of diffuse vasoconstriction may be contributory. The Stentys Coronary Stent System includes a self-expanding bare metal (nitinol) stent on a rapid exchange (RX) delivery system. In view of the theoretical implications of malapposition, the self-expanding property may offer a potential benefit.

This study is designed to evaluate the safety and effectiveness of the Stentys Coronary Stent System in the treatment of de novo stenotic lesions in coronary arteries in patients undergoing primary revascularization due to AMI as compared to the Multi-Link Vision™ coronary stent system (Abbott Vascular Inc. The study is powered for non-inferiority of the Stentys Coronary Stent System compared to the Vision Stent System.
The utility model provides a health care pillow core and a pillow, wherein the health care pillow core is internally provided with a traditional Chinese medicine inserting bag which is internally provided with a traditional Chinese medicinal bag. The health care pillow core is divided into a neck supporting area D, a side sleeping area A, a side sleeping area C, a traditional Chinese medicine inserting bag B and a neck supporting area F by a vertical lining. A medicinal bag adjusting pad can be inserted in the traditional Chinese medicine inserting bag so as to adjust the height of the traditional Chinese medicine inserting bag area. On the other hand, the utility model provides a health care pillow comprising a pillowcase and the health care pillow core. A pillow core adjusting pad can be inserted between the back side of the pillowcase and the health care pillow core for adjusting the height of the pillow. The health care pillow core and the pillow can satisfy different requirements of morpheus obstacle people and users and effectively improve the sleep quality.
Subjects aged 11-12 year old received 3 doses of Infanrix-IPV+Hib and Engerix-B vaccines in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
<P>PROBLEM TO BE SOLVED: To provide an aerosol agent containing percutaneous absorption medicine restrained from the occurrence of dripping at an applied part.  <P>SOLUTION: A button 1 is pressed down to apply force to a valve through a stem 5 to thereby open the valve, and the content sealed in a container 6 is jetted in mist, paste, or the like from a nozzle hole 2. In this case, protrusions 3 provided on both sides of the nozzle hole act as baffles, and the content is jetted in a jet pattern spreading flat in a longitudinal direction. The aerosol agent can be widely used for medication means by percutaneous absorption such as external administration or inhalation administration and is applicable for prevention and treatment of various diseases, relaxation of various symptoms, etc. according to the kind or the like of percutaneous absorption medicine in use.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders predominantly characterized by impaired corticosteroid synthesis. Clinical phenotypes include hypoadrenocorticism, electrolyte disturbances, abnormal gonadal development, and short stature, of which severe hyponadrenocorticism and salt wasting can be life-threatening. Genetic analysis can help in the clinical diagnosis of CAH. However, the 21-OHD-causing gene CYP21A2 is arranged in tandem with the highly homologous CYP21A1P pseudogene, making it difficult to determine the exact genotypes using the traditional method of multiplex ligation-dependent probe amplification (MLPA) plus Sanger sequencing or next-generation sequencing (NGS). We applied a long-read sequencing-based approach termed comprehensive analysis of CAH (CACAH) to 48 newborns with CAH that were diagnosed by clinical features and the traditional MLPA plus Sanger sequencing method for retrospective analysis, to evaluate its efficacy in the clinical diagnosis of neonatal CAH. Compared with the MLPA plus Sanger sequencing method, CACAH showed 100 % consistency in detecting SNV/indel variants located in exons and exon-intron boundary regions of CAH-related genes. It can directly determine the cis-trans relationship without the need to analyze parental genotypes, which reduces the time to diagnosis. Moreover, CACAH was able to distinguish different CYP21A1P/CYP21A2 and TNXA/TNXB chimeras, and detect additional variants (CYP21A2 variants c.-121C > T, c.*13G > A, c.*52C > T, c.*440C > T, c.*443 T > C, and TNXB variants c.12463 + 2 T > C, c.12204 + 5G > A). We also identified the TNXB variant c.11435_11524 + 30del alone instead of as a part of the TNXA/TNXB-CH-1 chimera in two newborns, which might be introduced by gene conversion. All of these characteristics enabled clinicians to better explain the phenotype of subjects and manage them more effectively. CACAH has a great advantage over the traditional MLPA and Sanger sequencing methods, showing substantial potential in the genetic diagnosis and screening of neonatal CAH.
Absorption: Following dental injection by the submucosal route of an articaine solution containing epinephrine 1:200,000, articaine reaches peak blood concentration about 25 minutes after a single dose injection and 48 minutes after three doses. Peak plasma levels of articaine achieved after 68 and 204 mg doses are 385 and 900 ng/mL, respectively. Following intraoral administration of a near maximum dose of 476 mg, articaine reaches peak blood concentrations of 2037 and 2145 ng/mL for articaine solution containing epinephrine 1:100,000 and 1:200,000, respectively, approximately 22 minutes post-dose.

Distribution: Approximately 60 to 80% of articaine HCl is bound to human serum albumin and ?-globulins at 37°C in vitro.

Metabolism: Articaine HCl is metabolized by plasma carboxyesterase to its primary metabolite, articainic acid, which is inactive. In vitro studies show that the human liver microsome P450 isoenzyme system metabolizes approximately 5% to 10% of available articaine with nearly quantitative conversion to articainic acid.

Excretion: At the dose of 476 mg of articaine, the elimination half-life was 43.8 minutes and 44.4 minutes for articaine solution containing epinephrine 1:100,000 and 1:200,000, respectively. Articaine is excreted primarily through urine with 53-57% of the administered dose eliminated in the first 24 hours following submucosal administration. Articainic acid is the primary metabolite in urine. A minor metabolite, articainic acid glucuronide, is also excreted in urine. Articaine constitutes only 2% of the total dose excreted in urine.

Special Populations: No studies have been performed to evaluate the pharmacokinetics of Articaine HCl 4% with epinephrine injection in pediatric subjects. There is insufficient information to determine whether the pharmacokinetics of Articaine HCl 4% with epinephrine injection differs by race.
Serious overdosage with hydromorphone hydrochloride tablets is characterized by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and sometimes bradycardia and hypotension. In serious overdosage, particularly following intravenous injection, apnea, circulatory collapse, cardiac arrest and death may occur.

In the treatment of overdosage, primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. A potentially serious oral ingestion, if recent, should be managed with gut decontamination. In unconscious patients with a secure airway, instill activated charcoal (30-100 g in adults, 1-2 g/kg in infants) via a nasogastric tube. A saline cathartic or sorbitol may be added to the first dose of activated charcoal.

Supportive measures (including oxygen, vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.

The opioid antagonist, naloxone, is a specific antidote against respiratory depression which may result from overdosage, or unusual sensitivity to hydromorphone hydrochloride tablets. Therefore, an appropriate dose of this antagonist should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. Naloxone should not be administered in the absence of clinically significant respiratory or circulatory depression. Naloxone should be administered cautiously to persons who are known, or suspected to be physically dependent on hydromorphone hydrochloride tablets. In such cases, an abrupt or complete reversal of narcotic effects may precipitate an acute withdrawal syndrome. Since the duration of action of hydromorphone hydrochloride tablets may exceed that of the antagonist, the patient should be kept under continued surveillance; repeated doses of the antagonist may be required to maintain adequate respiration. Apply other supportive measures when indicated.
The present invention provides for novel compounds of formula I, II, III and IV, as described herein. The present invention also provides for novel methods of manufacturing compounds of formula I, II and III from compounds of formula IV, that include contacting the compound of formula IV and an amino acid (or peptide). The present invention also provides for methods of killing or inhibiting a virus, bacteria and/or fungus. The methods include contacting a virus, bacteria and/or fungus, respectively, with a suitable amount of a compound of formula I, II or III. The present invention also provides for a method of treating a mammal afflicted with a viral infection, bacterial infection and/or fungal infection. The method includes administering to a mammal in need of such treatment an effective amount of a compound of formula I, II or III.
The study is randomised cross-over trial designed to compare: 1) Cognitive performances levels for four different e-Cigarette strength. Participants will be requested to abstain from smoking and alcohol from 20:00 on the night before each study day and from food and caffeine for at least 1 h before the session. On arrival at the study centre, carbon monoxide (CO) will be measured in participants' expired breath. If CO will be \>15 parts per million (ppm), the assigned study treatment will be allocated; however, if CO was \>15 ppm or they will report smoking in the previous 12 h, participants will be rescheduled wherever possible to a subsequent session.

On the first study day, participants will be randomised to use one of five ordered conditions: Electronic Nicotine Delivery Device (ENDD) (fourth generation) containing nicotine 2,4%; Electronic Nicotine Delivery Device (ENDD (second generation) containing nicotine 7,4 mg; Electronic Nicotine Delivery Device (ENDD containing nicotine 9 mg; Electronic Nicotine Delivery Device (ENDD nicotine free; their usual cigarette. Additionally participants will be trained to use an electronic cigarette. The following tests will be completed at the each visits: Continuous Performance Test - AX version (CPT-AX), Wisconsin card sorting test( WCST), Working memory test (N-BACK).
PURPOSE:To obtain a tooth surface treating agent, composed of a suspension prepared by dispersing a powdery cation exchange resin in an aqueous solution of a sulfate and enabling mechanical fitting and bonding by growing a crystal aggregate of gypsum on the tooth surface without damaging teeth simply by coating. CONSTITUTION:A suspension is obtained by dispersing a powdery cation exchange resin in an aqueous solution of a sulfate. The aforementioned cation exchange resin is preferably a polystyrene-based gel type strong acidic cation exchange resin, a phenolic strong acidic cation exchange resin, etc. The agent is used in a powdery form and the particle diameter thereof is preferably 150 mesh or below. The above-mentioned cation exchange resin is preferably dispersed at a concentration of >=1%. Ammonium sulfate is most suited as the sulfate and the concentration thereof is preferably 1-20%. Water to be used is preferably deionized water. In clinical use, the aforementioned agent is applied to an enamel agent, etc., brought into contact with tooth surfaces for 130sec and then washed with water.
FIELD: organic chemistry. SUBSTANCE: desired product has formula I where U represents C 1 -C 10 -alkoxycarbonyl, A represents C 1 -C 10 -alkyl or C 2 -C 10 -alkynyl having unsaturated carbon atom which is bound with indole; it may have substituents which are chosen of C 1 -C 10 -alkoxycarbonyl, phenyl being substituted or not by C 1 -C 10 -alkoxy group and by C 1 -C 10 -alkoxycarbonyl. (2-nitrophenyl)acetaldehyde having formula II where A represents radical with formula III where [C(O)OR h ]R h -C 1 -C 6 -alkyl and U - C(O)OR j , R j -C 1 -C 6 -alkyl is intermediate product. Method involves interaction of enamine with alkylating agent A-X having unsaturated carbon atom which is bound with leaving halide atom X and A is as it mentioned above. Said enamine has formula II where U is as it mentioned above, R-C 1 -C 4 -alkyl and two R radicals together with nitrogen to which they are bound form 1-pyrrolidynyl, 1-piperidynyl, 4-morpholynyl. To prepare compound having formula IV where A and U are the same as in compound I or IV it is necessary to carry out reaction of imine salt with reducing agent. Structure of mentioned above compounds I-IV is given in specification. EFFECT: improves efficiency of method.
This is a prospective, randomized, patient blinded trial of standard surgical retraction versus Mobius® retraction at cesarean delivery. Women will be approached by their provider at their 36 week prenatal visit regarding potential study participation. They will be given a letter describing the study. If a woman is interested, she will be contacted by a study nurse who will obtain informed consent. Ideally, women will be approached prior to the onset of labor or date of scheduled cesarean delivery so as to provide adequate time to review the study and ask questions. Women who undergo antenatal admission will be also approached by their provider regarding possible study participation and given a recruitment letter. If they are interested, then a study nurse will obtain informed consent.

Consenting women will be randomized after the decision to deliver by cesarean section is made. Randomization will be performed in blocks to control for scheduled versus unscheduled cesarean deliveries using a random numbers generator. Assignments will be kept in sequentially number opaque envelopes. Women will not be informed of their assignment until after discharge from the hospital. Efforts will be made in the operating room to avoid disclosing group assignment and the consent forms will not contain the specific name of the retractor under study. The operative team will be aware of group assignment.

Participants will complete a 7 item pain scale each post-operative day until discharge. This pain scale has been used in a pilot study and found to be accurate. The pain scale is a single page and takes less than 5 minutes to complete.

Charts will be reviewed to obtain clinical information which may have an impact on post-operative pain. This includes information about current and past substance abuse. Because of the increased amounts of post-operative pain experienced by women who use methadone during pregnancy, this group of women will be excluded from the study. To protect the information regarding substance abuse, a certificate of confidentiality has been obtained from the NIH.
FIELD: medical microbiology. SUBSTANCE: method deals with obtaining anthracic sera enabling to differentiate Bacillus anthracis against closely related microorganisms. Cell-free culture filtrate of Bacillus anthracis STI is concentrated upon ultrafilters HLP-10 and PM-10 by 150 times to achieve protein content in the filtrate being 8-10 mg/ml, then isolation of antigenic components is performed by gel filtration chromatography upon ultrafine sephacryl S-300 balanced with 0.3 M-NaCl solution with 0.025 M-tris-HCl buffer at 8.4 pH at registration of fractions' yield at λ = 280 nm. To obtain highly specific serum one should use an antigen of above 150 kDa molecular weight that corresponds to the first peak of fractions' yield. The obtained serum reacts in immunodiffusion reaction in gel with antigens of different variants of anthracic agent only that enables to identify anthracic agent against bacilli closely related according to their antigenic properties. EFFECT: higher efficiency of identification. 2 dwg, 4 ex
Regular exercise improves several functions, including cognition, in patients with stroke. However, the effect of regular exercise on neurogenesis related to cognition remains doubtful. We investigated the most effective exercise intensity for functional recovery after stroke using RNA sequencing following regular treadmill exercise. Photothrombotic cerebral infarction was conducted for 10-week-old male Sprague-Dawley rats (n = 36). A Morris water maze (MWM) test was performed before a regular treadmill exercise program (5 days/week, 4 weeks). Rats were randomly divided into four groups: group A (no exercise); group B (low intensity, maximal velocity 18 m/min); group C (moderate intensity, maximal velocity 24 m/min) and group D (high intensity, maximal velocity 30 m/min). After 4 weeks, another MWM test was performed, and all rats were sacrificed. RNA sequencing was performed with ipsilesional hippocampal tissue. On the day after cerebral infarction, no differences in escape latency and velocity were observed among the groups. At 4 weeks after cerebral infarction, the escape latencies in groups B, C, and D were shorter than in group A. The escape latencies in groups B and C were shorter than in group D. The velocity in groups A, B, and C was faster than in group D. Thirty gene symbols related to neurogenesis were detected (p < 0.05, fold change > 1.0, average normalized read count > four times). In the neurotrophin-signaling pathway, the CHK gene was upregulated, and the NF-κB gene was downregulated in the low-intensity group. The CHK and NF-κB genes were both downregulated in the moderate-intensity group. The Raf and IRAK genes were downregulated in the high-intensity group. Western blot analysis showed that NF-κB expression was lowest in the moderate-intensity group, whereas CHK and Raf were elevated, and IRAK was decreased in the high-intensity group. Moderate-intensity exercise may contribute to neuroplasticity. Variation in the expression of neurotrophins in neurogenesis according to exercise intensity may reveal the mechanism of neuroplasticity. Thus, NF-κB is the key neurotrophin for neurogenesis related to exercise intensity.
Composition and methods for improving air quality, disinfecting surfaces, and prevention of a respiratory infection. The method can decrease pathogen and/or parasitic concentrations in closed rooms and surfaces by the application of an antiseptic composition. The composition can be a pressurized or foaming solution containing a single terpene, a terpene mixture, and/or a liposome:terpene(s) combination with or without surfactant. The composition can be a true solution of an effective amount of an effective terpene and a carrier such as water. The composition can be a suspension or emulsion of terpene, surfactant, and carrier. Application can be, for example, by spraying a confined space with a solution of the present invention.
This is a prospective, randomized, two-arm study with the aim of assessing the effectiveness of compression or cooling in preventing higher-grade CIPN (\>Grade 2 according to EORTC) during weekly paclitaxel or nab-paclitaxel based (neo-)adjuvant chemotherapy. For this purpose, the dominant hand is either cooled or compressed, depending on the study arm, and the contralateral hand is only observed. The allocation to compression or cooling is done through randomization. In a second step, the effectiveness of cooling should be compared with compression. For this purpose, the data collected from the two study arms will be compared. Furthermore, patient satisfaction and quality of life during therapy will be examined. The primary study endpoint is the difference in moderate and severe polyneuropathy (CTCAE grade ≥ 2) compared between the control hand and the intervention hand within the study arms (extremity with cooling vs. control extremity or extremity with compression vs. control extremity). CIPN is evaluated via CTCAE criteria 4.0 and by the Total Neuropathy Score (TNS; clinical version). In addition, sensorimotor symptoms are documented using EORTC QLQ-CIPN20 questionnaires (see also 3.3).

In a second, hierarchical test, the rate of moderate and severe polyneuropathies is compared between the two intervention arms (cooling vs. compression). The rate of onychodystrophies and onycholysis in both intervention arms (compression and cooling) is documented using CTAE criteria and compared between the intervention arm and the control arm as well as between both patient groups.

In addition, patient satisfaction and acceptance of the intervention are examined. EORTC QLQ-C30 questionnaires are used to document quality of life. Any toxicities during therapy are documented according to the CTCAE criteria 4.0.
FIELD: medicine. ^ SUBSTANCE: non-infected fresh hen eggs are selected with their further incubating for 9 days. On 5, 6, 7 days hen egg is radiated for 30 s at frequency of modulation 9 Hz and radiation voltage 9 mW with further cooling of eggs for 6-7 days at temperature 2-4C and homogenisation of eggs. Obtained homogenate is subjected to processing by ultrasound in ultrasonic dispersant. To homogenate, processed with ultrasound, added is mixture, containing 0.1% solution of sodium benzoate and 0.1% of solution of potassium sorbate in equal parts, in weight ratio 1:1 respectively with further ultramicrofiltration through filters with 0.2 mcm diameter, obtaining biologically active substance for embryonic-egg mass. Homogeneous mass is prepared in the following way. Medical gelatin is covered with decoction, containing calendula decoction and chamomile decoction in weight ratio 1:1, keep at temperature 20-25C for 55-60 minutes with further placement of decoction with gelatin on water bath at temperature 65-70C until complete dissolusion of gelatin is obtained. Into obtained decoction with gelatin added are amikacin, furacilline, anesthesin, amaranth oil, glycerol and brilliant green with further mixing in homogeniser for 4-5 min obtaining homogeneous mass. To obtained homogeneous mass biologically active substance from embryonic-egg mass is added in specified ratio and mixed in homogeniser for 5-7 min. Obtained mass is poured into special vessels and are placed in thermostat for 3.5-4 hours at temperature 37-39C with further cooling for 1-2 days until plates solidify in form of plates. ^ EFFECT: inventions make it possible for injuries to regenerate quickly, increase immune reactivity of the organism and make it possible to simplify method of obtaining anti-burn plate. ^ 2 cl, 6 dwg, 2 tbl, 5 ex